Safety and efficacy of fresh whole blood donor lymphocyte infusion in children.

Abstract:

:Donor lymphocyte infusion (DLI) is a form of cellular immunotherapy which is known to be effective in preventing relapse in leukemia by inducing graft versus leukemia (GVL) effect. In hematopoietic stem cell transplantation (HSCT) for benign hematological conditions including primary immune deficiency, mixed chimerism is seen with the use of reduced intensity conditioning. DLI can help prevent graft rejection by boosting the existing graft in these situations. There is scant data on the use of DLI in children who have undergone HSCT for benign hematological disorders. We present our case series with early withdrawal of immunosuppression and DLI as a means to mitigate relapse of leukemia and prevent graft rejection in mixed chimerism in children transplanted for benign hematological disorders. Donor lymphocyte infusion was given in a graded regimen with the cell dose of 1 × 105 CD3 cells/kg (1 × 104/kg in haploidentical transplant), 5 × 105 CD3 cells/kg, 1 × 106 CD3 cells/kg depending on the graft kinetics and the clinical status of the children. A total of fifty eight children including those with haploidentical donors underwent DLI with an overall survival of 81.1%. The use of fresh whole blood in very small aliquots from the donor has made this technique cost effective and an attractive form of immunotherapy.

journal_name

Bone Marrow Transplant

authors

Swaminathan VV,Uppuluri R,Patel S,Sivashankaran M,Ravichandran N,Ramanan KM,Ramakrishnan B,Vaidhyanathan L,Raj R

doi

10.1038/s41409-019-0580-7

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

1892-1897

issue

11

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-019-0580-7

journal_volume

54

pub_type

临床试验,杂志文章
  • Alternative donor SCT for the treatment of MHC class II deficiency.

    abstract::MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.140

    authors: Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

    更新日期:2013-02-01 00:00:00

  • Thyroid function after autologous bone marrow transplantation.

    abstract::Thyroid function was prospectively analysed in 111 consecutive patients in relation to autologous bone marrow transplantation (ABMT). Median follow-up time was 12 (range 3-60) months. As part of the conditioning treatment 58 patients had received total body irradiation (TBI) as a single dose of 7.5 Gy (dose rate 0.15 ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Carlson K,Lönnerholm G,Smedmyr B,Oberg G,Simonsson B

    更新日期:1992-08-01 00:00:00

  • Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.

    abstract::We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705922

    authors: Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

    更新日期:2008-03-01 00:00:00

  • Adenovirus infection after pediatric bone marrow transplantation.

    abstract::Retrospective analysis of 206 patients undergoing 215 consecutive bone marrow transplants (BMT) at St Jude Children's Research Hospital between November 1990 and December 1994 identified 6% (seven male, six female) with adenovirus infection. The affected patients had a median age of 7.9 years (range 3-24 years) at tim...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1701563

    authors: Hale GA,Heslop HE,Krance RA,Brenner MA,Jayawardene D,Srivastava DK,Patrick CC

    更新日期:1999-02-01 00:00:00

  • Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.

    abstract::Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702378

    authors: Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

    更新日期:2000-05-01 00:00:00

  • The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.

    abstract::We treated 12 patients with chronic myelogenous leukemia (CML) with a low-intensity preparative regimen followed by allogeneic stem cell transplantation in an attempt to confer a curative graft-versus-leukemia (GVL) effect with minimum morbidity. Seven patients in first chronic phase (CP1) and five in second chronic p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1704231

    authors: Sloand E,Childs RW,Solomon S,Greene A,Young NS,Barrett AJ

    更新日期:2003-11-01 00:00:00

  • Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.

    abstract::The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches. ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705888

    authors: Shaw BE,Russell NH

    更新日期:2008-03-01 00:00:00

  • Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?

    abstract::Our purpose was to assess success rates in children of achieving optimal hematopoietic progenitor cells (HPCs) harvest after mobilization with 300 microg/kg pegfilgrastim. Between January 2005 and January 2007, 26 children with solid malignancies who were referred for HPC collection were consecutively included. Hemato...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.412

    authors: Merlin E,Zohar S,Jérôme C,Veyrat-Masson R,Marceau G,Paillard C,Auvrignon A,Le Moine P,Gandemer V,Sapin V,Halle P,Boiret-Dupré N,Chevret S,Deméocq F,Dubray C,Kanold J

    更新日期:2009-06-01 00:00:00

  • Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.

    abstract::Between May 1994 and May 2000, we autotransplanted 48 consecutive patients, 21 females and 27 males aged over 60 years (range: 60-78, median: 63). Sixteen patients had multiple myeloma (MM), 14 high-grade non-Hodgkin's lymphoma (HGNHL), six low-grade non-Hodgkin's lymphoma (LGNHL), nine acute myeloid leukemia (AML), o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703034

    authors: Olivieri A,Capelli D,Montanari M,Brunori M,Massidda D,Poloni A,Lucesole M,Centurioni R,Candela M,Masia MC,Tonnini C,Leoni P

    更新日期:2001-06-01 00:00:00

  • Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.

    abstract::On January 20, 2020, the first patient with coronavirus disease 2019 (COVID-19) in the United States of America was diagnosed in Washington state, which subsequently experienced rapidly increasing numbers of COVID-19 cases, hospitalizations, and deaths. This placed the Seattle Blood and Marrow Transplant Program at Fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-01068-x

    authors: Ueda Oshima M,Sandmaier BM,Petersdorf E,Flowers ME,Hill GR,Lee SJ,Appelbaum FR,Carpenter PA,Baker KS,Connelly-Smith L,McCool A,Elgar S,Pergam SA,Liu C,Stewart FM,Mielcarek M

    更新日期:2020-09-26 00:00:00

  • Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers.

    abstract::Hematopoietic progenitor cell levels were monitored in the peripheral blood of ten healthy adults receiving a single dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The objective was to determine the time and number of progenitor cells released into the peripheral blood, induced by a single ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schwinger W,Mache C,Urban C,Beaufort F,Töglhofer W

    更新日期:1993-06-01 00:00:00

  • Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.

    abstract::PBSCs are usually mobilized using G-CSF with or without chemotherapy. With the emergence of newer mobilizing agents, predicting poor mobilization may allow early intervention and prevent the costs and complications associated with remobilization. We retrospectively evaluated a cohort of 1556 patients seen between Janu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.236

    authors: Sinha S,Gastineau D,Micallef I,Hogan W,Ansell S,Buadi F,Dingli D,Dispenzieri A,Gertz M,Greiner C,Hayman S,Inwards D,Johnston P,Lacy M,Litzow M,Porrata L,Winters JL,Kumar S

    更新日期:2011-07-01 00:00:00

  • Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.

    abstract::Serum concentrations of Anti-Müllerian hormone (AMH) and Inhibin B were used to assess potential fertility in survivors of childhood haematopoietic stem cell transplantation (HSCT) after three chemotherapy-conditioning regimens of differing intensity. Of 428 patients transplanted between 1990-2012 for leukaemia and im...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0866-9

    authors: Leiper A,Houwing M,Davies EG,Rao K,Burns S,Morris E,Laven J,van der Kooi AL,van den Heuvel Eibrink M,Nussey S

    更新日期:2020-10-01 00:00:00

  • Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

    abstract::Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.33

    authors: Milone G,Poidomani M,Leotta S,Avola G,Camuglia MG,Privitera A,Consoli C,Mercurio S,Romeo MA,Di Marco A,Di Mercurio S,Spadaro A,Palumbo GA,Tedeschi P

    更新日期:2012-01-01 00:00:00

  • Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

    abstract::Reduced-intensity conditioning (RIC) extends hematopoietic stem cell transplants (HSCT) to elderly or debilitated patients who are not candidates for HSCT. The incidence and outcomes of cardiac complications have been reported following myeloablative HSCT. We assessed the incidence and outcomes of cardiac complication...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.97

    authors: Peres E,Levine JE,Khaled YA,Ibrahim RB,Braun TM,Krijanovski OI,Mineishi S,Abidi MH

    更新日期:2010-01-01 00:00:00

  • The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.

    abstract::In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705846

    authors: Nasilowska-Adamska B,Rzepecki P,Manko J,Czyz A,Markiewicz M,Federowicz I,Tomaszewska A,Piatkowska-Jakubas B,Wrzesien-Kus A,Bieniaszewska M,Duda D,Szydlo R,Halaburda K,Szczepinski A,Lange A,Hellman A,Robak T,Skotnicki A

    更新日期:2007-11-01 00:00:00

  • Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus.

    abstract::Our previous data have revealed that proteinuria, antinuclear antibodies and anti-dsDNA antibodies in refractory systemic lupus erythematosus (SLE) reduced after MSC infusion. This study focused on the roles of mesenchymal SCT (MSCT) in SLE patients with refractory cytopenia. Thirty-five SLE patients with refractory c...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2012.184

    authors: Li X,Wang D,Liang J,Zhang H,Sun L

    更新日期:2013-04-01 00:00:00

  • Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

    abstract::The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.73

    authors: Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

    更新日期:2012-02-01 00:00:00

  • The number of circulating CD34+ blood cells predicts the colony-forming capacity of leukapheresis products in children.

    abstract::In children, only a few guidelines are available for optimizing peripheral blood progenitor cell (PBPC) harvesting. We analyzed by means of flow cytometry and clonogenic assays 60 harvest products obtained from 20 children by standardized leukapheresis after treatment with chemotherapy and CSF. In addition, 27 fresh b...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Leibundgut K,von Rohr A,Brülhart K,Hirt A,Ischi E,Jeanneret C,Muff J,Ridolfi-Lüthy A,Wagner HP,Tobler A

    更新日期:1995-01-01 00:00:00

  • Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases.

    abstract::Persistent thrombocytopenia and thrombotic complications are commonly observed in bone marrow transplant (BMT) patients. We describe two incidents following BMT in which heparin may have played a contributory role. One patient developed subclavian venous thrombosis following autologous BMT in spite of the severe throm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Tezcan AZ,Tezcan H,Gastineau DA,Armitage JO,Haire WD

    更新日期:1994-09-01 00:00:00

  • Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

    abstract::The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701272

    authors: Moreau P,Milpied N,Voillat L,Colombat P,Mahé B,Rapp MJ,Moreau A,Dupas B,Bulabois CE,Juge-Morineau N,Harousseau JL

    更新日期:1998-06-01 00:00:00

  • Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.

    abstract::Introduction of genes conferring drug resistance into hematopoietic cells may allow for improved chemotherapy by protection of normally drug-sensitive cells from the toxic side-effects of antitumor agents. We recently reported that transplantation of murine marrow transgenic for drug-resistant dihydrofolate reductase ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701984

    authors: James R,May C,Diers M,Wagner J,McIvor R

    更新日期:1999-10-01 00:00:00

  • IL-21 is critical for GVHD in a mouse model.

    abstract::Immunological effects of IL-21 on T, B and natural killer (NK) cells have been reported, but the role of IL-21 in GVHD remains obscure. Here, we demonstrate that morbidity and mortality of GVHD was significantly reduced after BMT with splenocytes from IL-21R(-/-) mice compared with those from wild type mice. To furthe...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.223

    authors: Meguro A,Ozaki K,Oh I,Hatanaka K,Matsu H,Tatara R,Sato K,Leonard WJ,Ozawa K

    更新日期:2010-04-01 00:00:00

  • Value and affordability of CAR T-cell therapy in the United States.

    abstract::In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-0956-8

    authors: Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

    更新日期:2020-09-01 00:00:00

  • Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis.

    abstract::We prospectively studied absolute lymphocyte (ALC) and monocyte counts (AMC), lymphocyte subsets and proliferative in vitro responses to mitogen and antigen in 12 patients with AL-amyloidosis (AL) undergoing autologous blood stem cell transplantation (SCT) with high-dose i.v. melphalan. Myeloid and lymphoid recovery (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703298

    authors: Akpek G,Lenz G,Lee SM,Sanchorawala V,Wright DG,Colarusso T,Waraska K,Lerner A,Vosburgh E,Skinner M,Comenzo RL

    更新日期:2001-12-01 00:00:00

  • Pneumoperitoneum without peritonitis after allogeneic peripheral blood stem cell transplantation.

    abstract::Allogeneic blood stem cell transplantation is associated with multiple complications. We report a case of pneumoperitoneum without peritonitis associated with colonic pneumatosis in a patient who had undergone an allogeneic peripheral blood cell transplant ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701255

    authors: de Magalhaes-Silverman M,Simpson J,Ball E

    更新日期:1998-06-01 00:00:00

  • Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.

    abstract::This study evaluated delivery of involved field radiotherapy (IFRT) with transplantation for lymphomas timed to minimise toxicity. Patients transplanted for lymphoma had infradiaphragmatic disease irradiated pre-transplant and supradiaphragmatic disease post transplant. A total of 31 patients were studied, with a medi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.bmt.1704759

    authors: Wirth A,Prince HM,Wolf M,Stone JM,Matthews J,Gibson J,Macleod C,Szer J,Grigg A,To B,Roos D,Schwarer AP,Davis S,Australasian Leukaemia and Lymphoma Group.

    更新日期:2005-02-01 00:00:00

  • Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.

    abstract::With the increasing frequency of haploidentical transplantation, it is becoming more important to establish the degree of HLA mismatch that can be accepted. We retrospectively analyzed clinical data of 50 adult Japanese patients with high-risk hematologic malignancies who underwent allogeneic peripheral blood stem cel...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704342

    authors: Yamasaki S,Ohno Y,Taniguchi S,Yoshida T,Hayashi S,Ogawa H,Shimazaki C,Takahashi S,Kasai M,Wake A,Nishimura M,Tokunaga K,Gondo H,Takaue Y,Harada M,Mineishi S,Japanese group for blood and marrow transplantation.

    更新日期:2004-02-01 00:00:00

  • Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy.

    abstract::Treatment of autoimmune disease with bone marrow transplantation (BMT) is under investigation. A few reports of patients undergoing allogeneic BMT for malignant conditions observed the resolution of psoriasis after BMT, with minimal late morbidity. We describe a patient with chronic myelogenous leukemia (CML) whose ps...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702703

    authors: Adkins DR,Abidi MH,Brown RA,Khoury H,Goodnough LT,Vij R,Westervelt P,DiPersio JF

    更新日期:2000-12-01 00:00:00

  • Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.

    abstract::Conditioning including total body/lymphoid irradiation is widely used to prevent graft rejection in patients with refractory severe aplastic anemia (SAA) undergoing hemopoietic cell transplantation (HCT) from alternative donors and or after graft manipulation. To reduce regimen-related toxicity we transplanted three c...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704792

    authors: Urban C,Benesch M,Sykora KW,Schwinger W,Lackner H

    更新日期:2005-03-01 00:00:00